Adjustment for index event bias in genome-wide association studies of subsequent events.
- Authors
- Dudbridge, Frank; Allen, Richard J; Sheehan, Nuala A; Schmidt, A Floriaan; Lee, James C; Jenkins, R Gisli; Wain, Louise V; Hingorani, Aroon D; Patel, Riyaz S
- Year
- 2019
- Journal
- Nature communications
- PMID
- 30952951
- DOI
- 10.1038/s41467-019-09381-w
- PMCID
- PMC6450903
Following numerous genome-wide association studies of disease susceptibility, there is increasing interest in genetic associations with prognosis, survival or other subsequent events. Such associations are vulnerable to index event bias, by which selection of subjects according to disease status creates biased associations if common causes of incidence and prognosis are not accounted for. We propose an adjustment for index event bias using the residuals from the regression of genetic effects on prognosis on genetic effects on incidence. Our approach eliminates this bias when direct genetic effects on incidence and prognosis are independent, and otherwise reduces bias in realistic situations. In a study of idiopathic pulmonary fibrosis, we reverse a paradoxical association of the strong susceptibility gene MUC5B with increased survival, suggesting instead a significant association with decreased survival. In re-analysis of a study of Crohn's disease prognosis, four regions remain associated at genome-wide significance but with increased standard errors.
Directed acyclic graph of association of SNP G with prognosis Y conditional on incidence X. U is a composite variable including all common causes of X and Y, and may include polygenic effects as well as non-genetic risk factors. In our examples, X is idiopathic pulmonary fibrosis or Crohnβs disease, and Y is survival or prognosis. Conditioning on X induces the moralised association between G with U shown by the dotted line. This creates association between G and Y via the path \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$G - U \to Y$$\end{document}G-UβY in addition to the direct effect G \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\to$$\end{document}β Y
Directed acyclic graph of association of SNP G with risk factor X conditional on outcome Y. U is as in Fig. 1. For example, X may be body mass index, and Y may be type-2 diabetes, with the study design being case/control or a cohort depleted for cases, such as UK Biobank17. Conditioning on Y induces the moralised association between G and U shown by the dotted line. This creates association of G with X via the path \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$G - U \to X$$\end{document}G-UβX, in addition to the direct effect G \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\to$$\end{document}β X. The direct effect itself is biased by conditioning on Y, as shown by the additional dotted line connecting G and X. The resulting selection bias is not the focus of this paper
Directed acyclic graph of association of SNPs Gi with prognosis Y conditional on incidence X. U is as in Fig. 1. Conditioning on X induces the moralised associations shown by dotted lines. These create association of each Gi with Y via the path \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$G_i - U \to Y$$\end{document}Gi-UβY and all paths \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$G_i - G_j \to Y$$\end{document}Gi-GjβY where \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$i \ne j$$\end{document}iβ j. Under a polygenic model in which individual SNPs explain little covariation between X and Y, the combined effect of U and all \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$G_{j \ne i}$$\end{document}Gjβ i is approximately constant across SNPs Gi. If a SNP Gk has a major effect on X and/or Y, the associations of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$G_{j \ne k}$$\end{document}Gjβ k can be conditioned on Gk to prevent the major gene contributing to index event bias
Association of SNP G with prognosis Y conditional on incidence X derived from trait S. U is a composite variable as in Fig. 1. For example, X may be a diagnosis of disease (e.g., Crohnβs disease), and S a subtype of disease (e.g., ileal, colonic, ileocolonic or healthy). Conditioning on X, which is a descendant of the collider S, induces the moralised association between G and U shown by the dotted line. This creates association of G with Y via the path \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$G - U \to Y$$\end{document}G-UβY in addition to its direct effect via G \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\rightarrow$$\end{document}β Y and its mediated effect via \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$G \to S \to Y$$\end{document}GβSβY. Further conditioning on S blocks the mediation path \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$G \to S \to Y$$\end{document}GβSβY, but leaves open the path \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$G - U \to Y$$\end{document}G-UβY creating index event bias
| # | Section | Preview |
|---|---|---|
| 80 | Methods β Idiopathic pulmonary fibrosis | \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt}β¦ |
| 81 | Methods β Crohnβs disease | We downloaded summary statistics for incidence29 (5956 cases and 14,927 controls) and prognosis6β¦ |
| 82 | Supplementary information | Supplementary information peer review file Description of Additional Supplementary Files⦠|
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| A large-scale genome-wide association study meta-analysis of cannabis use disorder. | 2020 | 33096046 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Challenges and future directions for Mendelian randomization. | Sanderson E et al. | β | 2026 | β |
| Adiposity and domain-specific stroke recovery: A Mendelian randomization study. | Wang M et al. | β | 2025 | β |
| An application of the MR-Horse method to reduce selection bias in genome-wide association studies of disease progression. | Donovan K et al. | β | 2025 | β |
| Assessment and ascertainment in psychiatric molecular genetics: challenges and opportunities for cross-disorder research. | Cai N et al. | β | 2025 | β |
| Association between polygenic risk and survival in breast cancer patients. | Kurant DE et al. | β | 2025 | β |
| Estimating Causal Effects on a Disease Progression Trait Using Bivariate Mendelian Randomisation. | Cai S et al. | β | 2025 | β |
| Genetic predisposition to altered blood cell homeostasis is associated with glioma risk and survival. | Kachuri L et al. | β | 2025 | β |
| Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups. | Hoffmann TJ et al. | β | 2025 | β |
| Investigating the association between anthropometry and colorectal cancer survival: a two-sample Mendelian randomization analysis. | Kanellopoulou A et al. | β | 2025 | β |
| Limited overlap between genetic effects on disease susceptibility and disease survival. | Yang Z et al. | β | 2025 | β |
| MUC5B promoter variant and survival in rheumatoid arthritis-associated interstitial lung disease. | Klein J et al. | β | 2025 | β |
| Prospects of Mendelian randomization in hepatology: a comprehensive literature review with practice guidance. | Chen L et al. | β | 2025 | β |
| The Dawn of Precision Medicine in Fibrotic Interstitial Lung Disease. | Karampitsakos T et al. | β | 2025 | β |
| Unbiased causal inference with Mendelian randomization and covariate-adjusted GWAS data. | Wang P et al. | β | 2025 | β |
| Association between polygenic risk and survival in breast cancer patients | Kurant DE et al. | β | 2024 | β |
| Biomarkers That Predict Crohn's Disease Outcomes. | Olivera PA et al. | β | 2024 | β |
| Collider bias correction for multiple covariates in GWAS using robust multivariable Mendelian randomization. | Wang P et al. | β | 2024 | β |
| Fecal microbiota composition is a better predictor of recurrent Clostridioides difficile infection than clinical factors in a prospective, multicentre cohort study. | van Rossen TM et al. | β | 2024 | β |
| Genetic Complexities of Cerebral Small Vessel Disease, Blood Pressure, and Dementia. | Sargurupremraj M et al. | β | 2024 | β |
| Genetic liability to frailty in relation to functional outcome after ischemic stroke. | Cai H et al. | β | 2024 | β |
| Identification and correction for collider bias in a genome-wide association study of diabetes-related heart failure. | Sun YV et al. | β | 2024 | β |
| Mendelian Randomization Applied to Neurology: Promises and Challenges | Gagnon E et al. | β | 2024 | β |
| Nonlinear relationship between high-density lipoprotein cholesterol and cardiovascular disease: an observational and Mendelian randomization analysis. | Chen JX et al. | β | 2024 | β |
| Screening embryos for polygenic disease risk: a review of epidemiological, clinical, and ethical considerations. | Capalbo A et al. | β | 2024 | β |
| Shared and Distinct Genomics of Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Embolism. | Liley J et al. | β | 2024 | β |
| Two sample Mendelian Randomisation using an outcome from a multilevel model of disease progression. | Lawton M et al. | β | 2024 | β |
| A framework for assessing selection and misclassification bias in mendelian randomisation studies: an illustrative example between body mass index and covid-19. | Clayton GL et al. | β | 2023 | β |
| Biomarkers Associated With Severe COVID-19 Among Populations With High Cardiometabolic Risk: A 2-Sample Mendelian Randomization Study. | Sood T et al. | β | 2023 | β |
| Genetically adjusted PSA levels for prostate cancer screening. | Kachuri L et al. | β | 2023 | β |
| Genetic Variants, Serum 25-Hydroxyvitamin D Levels, and Sarcopenia: A Mendelian Randomization Analysis. | Sha T et al. | β | 2023 | β |
| Idiopathic pulmonary fibrosis and the role of genetics in the era of precision medicine. | Alonso-Gonzalez A et al. | β | 2023 | β |
| Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model. | Mavaddat N et al. | β | 2023 | β |
| <i>MUC5B</i>, telomere length and longitudinal quantitative interstitial lung changes: the MESA Lung Study. | Kim JS et al. | β | 2023 | β |
| MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis. | van der Vis JJ et al. | β | 2023 | β |
| PCSK6 and Survival in Idiopathic Pulmonary Fibrosis. | Oldham JM et al. | β | 2023 | β |
| Precision medicine advances in idiopathic pulmonary fibrosis. | Karampitsakos T et al. | β | 2023 | β |
| Quality control and analytic best practices for testing genetic models of sex differences in large populations. | Khramtsova EA et al. | β | 2023 | β |
| Reassessing the association of MUC5B with survival in idiopathic pulmonary fibrosis. | Cai S et al. | β | 2023 | β |
| Strategies to investigate and mitigate collider bias in genetic and Mendelian randomisation studies of disease progression. | Mitchell RE et al. | β | 2023 | β |
| Vitamin D deficiency and C-reactive protein: a bidirectional Mendelian randomization study. | Zhou A et al. | β | 2023 | β |
| Adjusting for collider bias in genetic association studies using instrumental variable methods. | Cai S et al. | β | 2022 | β |
| Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. | Liu GY et al. | β | 2022 | β |
| A Guide for Understanding and Designing Mendelian Randomization Studies in the Musculoskeletal Field. | Hartley AE et al. | β | 2022 | β |
| A <i>MUC5B</i> Gene Polymorphism, rs35705950-T, Confers Protective Effects Against COVID-19 Hospitalization but Not Severe Disease or Mortality. | Verma A et al. | β | 2022 | β |
| A robust method for collider bias correction in conditional genome-wide association studies. | Mahmoud O et al. | β | 2022 | β |
| Associations of the MUC5B promoter variant with timing of interstitial lung disease and rheumatoid arthritis onset. | McDermott G et al. | β | 2022 | β |
| A theory-based practical solution to correct for sex-differential participation bias. | Lee H et al. | β | 2022 | β |
| Exploring and mitigating potential bias when genetic instrumental variables are associated with multiple non-exposure traits in Mendelian randomization. | Yang Q et al. | β | 2022 | β |
| Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting. | Seviiri M et al. | β | 2022 | β |
| HMOX1 genetic polymorphisms and outcomes in infectious disease: A systematic review. | Hamilton FW et al. | β | 2022 | β |
| How Do We Predict a Patient's Disease Course and Whether They Will Respond to Specific Treatments? | Verstockt B et al. | β | 2022 | β |
| Leveraging global multi-ancestry meta-analysis in the study of idiopathic pulmonary fibrosis genetics. | Partanen JJ et al. | β | 2022 | β |
| Mendelian randomisation for psychiatry: how does it work, and what can it tell us? | Wootton RE et al. | β | 2022 | β |
| Mendelian Randomization: Concepts and Scope. | Richmond RC et al. | β | 2022 | β |
| Mitochondrial DNA Copy Number as a Marker and Mediator of Stroke Prognosis: Observational and Mendelian Randomization Analyses. | Chong MR et al. | β | 2022 | β |
| Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk. | Zhou A et al. | β | 2022 | β |
| Short- and intermediate-term exposure to ambient fine particulate elements and leukocyte epigenome-wide DNA methylation in older men: the Normative Aging Study. | Wang C et al. | β | 2022 | β |
| Stroke genetics informs drug discovery and risk prediction across ancestries. | Mishra A et al. | β | 2022 | β |
| Towards Treatable Traits for Pulmonary Fibrosis. | Hoffman TW et al. | β | 2022 | β |
| Untangling 11p15.5 for Chronic Hypersensitivity Pneumonitis. | Allen RJ | β | 2022 | β |
| Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response. | Bowman WS et al. | β | 2021 | β |
| Exploiting collider bias to apply two-sample summary data Mendelian randomization methods to one-sample individual level data. | Barry C et al. | β | 2021 | β |
| Genetic analyses identify widespread sex-differential participation bias. | Pirastu N et al. | β | 2021 | β |
| Genetic predictors of participation in optional components of UK Biobank. | Tyrrell J et al. | β | 2021 | β |
| Mendelian Randomization Focused Analysis of Vitamin D on the Secondary Prevention of Ischemic Stroke. | Chan YH et al. | β | 2021 | β |
| Mendelian randomization for studying the effects of perturbing drug targets. | Gill D et al. | β | 2021 | β |
| MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression. | Juge PA et al. | β | 2021 | β |
| Shared genetic etiology between idiopathic pulmonary fibrosis and COVID-19 severity. | Fadista J et al. | β | 2021 | β |
| A framework for transcriptome-wide association studies in breast cancer in diverse study populations. | Bhattacharya A et al. | β | 2020 | β |
| A large-scale genome-wide association study meta-analysis of cannabis use disorder. | Johnson EC et al. | β | 2020 | β |
| Genetic Risk Factors for Idiopathic Pulmonary Fibrosis: Insights into Immunopathogenesis. | Michalski JE et al. | β | 2020 | β |
| Mucins and their receptors in chronic lung disease. | Denneny E et al. | β | 2020 | β |
| Nanoengineered immunosuppressive therapeutics modulating M1/M2 macrophages into the balanced status for enhanced idiopathic pulmonary fibrosis therapy. | Chang X et al. | β | 2020 | β |
| Polygenic risk scores for coronary artery disease and subsequent event risk amongst established cases. | Howe LJ et al. | β | 2020 | β |
| Sources of bias in genomics research of oral and dental traits. | Agler CS et al. | β | 2020 | β |
| Unraveling the role of MUC5B in idiopathic interstitial pneumonias (IIPs). | Dobrinskikh E et al. | β | 2020 | β |
| Use of Multivariable Mendelian Randomization to Address Biases Due to Competing Risk Before Recruitment. | Schooling CM et al. | β | 2020 | β |
| Guidelines for performing Mendelian randomization investigations: update for summer 2023. | Burgess S et al. | β | 2019 | β |
| Translational research in pulmonary fibrosis. | Mathai SK et al. | β | 2019 | β |
| Within family Mendelian randomization studies. | Davies NM et al. | β | 2019 | β |